\([a-zA-Z]+\,\s\d{4}\)
\([a-zA-Z]+\s\d\)
Table\s?\d+
SPSS\s\d{2}\.\d
\d\,\d\-diazabicyclo
\d+\-well
cat\s\d+
DH\d+B
RPMI-\d+
\([a-zA-Z]+\sand\s[a-zA-Z]+\,\s\d{4}\)
\(CF\d+A\)
\d+\sU/ml
\[\d{3}\]
COVID-19
\[\d{2}\,\s\d{2}\]
\[\d{2}\]
\(ENA\)\-\d+
peptide\-1
MCP\-1
Th\d+
\[\d\,\s\d{2}\]
\[\d\]
\[\d\,\s\d\,\s\d\]
p\d+
Fig\.\s{1,2}\d{1,2}
\s\d{2}\sh\s
protein\-\d+
Staining \d+
Chapter\s\d+
\d+ kHz
\d+ MPa
\d+-min
\d+ log
MS\d
\d+ and \d+
disease \d{4}
GGII\.4
19\d{2}\-19\d{2}
20\d{2}\-20\d{2}
20\d{2}/20\d{2}
ORF\d
August\s20\d{2}
years\s19\d{2}
Section\s\d\.\d\.\d\.
In\s20\d{2}
April\s20\d{2}
\(20\d{2}\)
Section\s\d\.\d
section\s\d\.\d\.\d\.
in\s19\d{2}
over\s\d+\speople
\d+\shours
January\s\d{4}
March\s\d{4}
\d+\-day
3D
below \d+
(April \d+, \d+)|(April \d+)
\d{4}/\d+
\(USNRC\s2016\)
Unit\s\d
Fig\.\s\d\s\.\d
March\s\d{1,2}\,\s\d{4}
in\s20\d{2}
\d{1,2}\smonths
\(19\d{2}\)
\([a-zA-Z]+\s20\d{2}\s?\)
\([a-zA-Z]+\s\d{4}\)
\d{1,2}(\.\d{1,2})?\scm
\[\d{1,2}\]
\[\d\,\s\d\]
PfSWIB\-C2
PfSWIB\-B10
file\s\d{1,2}
Table\sS\d{1,2}
FK506
Day\s\d+
3'UTR
\d{1,2}\sweek(s)?
\d{1,2}\sms
\d{1,2}\smin
\d{1,}\ss
\d{1,2}\scycles
\d%\sRBC
CO\s?2
herpesvirus\-1
\d+\sppm
\(Fig\.\s\d{1,2}\.\d{1,2}\)
\d+ MHz
\d+ mg
ALDEx\d+
ggplot\d+
GFF\d
PlasmoDB-\d+
Pfalciparum\dD\d+
\d+ °C
\d \+ \d
\d+ μg
RPMI 1640
\d+ mM
lines \dD\d
\d+-h
h?BAF\d+[ab]?
PfSIP\d+
ApiAP\d+
SPE\d+
PF11_\d{4}
PfSET\d+
H\dK\d+me4
\[\d{1,3}, \d{1,3}, \d{1,3}\]
PfSir\d+[A-Za-z]
Sir\d
PfGCN\d+
H\d{1,2}K\d{1,2}
K\d{1,2}
histone \d{1,2}
lysine \d{1,2}
\d{1,2}'UTR
lysine\d{1,2}
PfEMP\d{1,2}
\d+ members
protein \d+
\d{1,2} patients
\d{1,2}% of
\d+-log
VP\d
\d+ copies
ORF \d+
\d+'untranslated
\d, \d, and \d
over \d{1,2}
approximately \d+\.\d+ kb
other \d
\d+ h
\d+ patients
factor-\d+
CD\d
H\d{1,3}Y
M\d+
\d+ mares
\d+ foals
\d Quarter
\([a-zA-Z]+ \d{4}\s?\)
in \d+
of \d+
\d{1,3} vars
log \d
\d{1,3} var
\d{1,2} upsB
shield\d
\d{1,3} kDa
v\d+\.\d+\.\d+
QuantStudio \d
Shield\d
\d+ µl
\d+ ml
Title \d+
infections \d{1,3}
December \d{4}
coronavirus-2
Disease \d{4} 
\d{1,3}°C
Tween \d+
\d{1,3} times
subtracting \d+\.\d+
H\dP0\d
\d{1,3} filter
\d{1,2}\.\d{1,2} trypsin
of \d+\.\d+
\d{1,3}\.\d{1,3} mab
ts\d{3}
COVID-19
[Ss]ection\s\d[\.\d]*
the\s\d{4}
Table  \d
TLR\d
mDC\d
\(\d{3}\)
\(\d{3}\, \d{3}\, \d{3}\)
IL-\d{1,3}
BATF\d{1,3}
CLEC\dA
XCR\d
BDCA-\d
\(\d{2}\)
\(\d{3}\,\s?\d{3}\)
Th\d{1,3}
IRF\d{1,3}
KLF\d{1,3}
type-\d{1,3}
\(\d{2}\,\s?\d{2}\,\s?\d{2}\)
\(\d{2}\,\s?\d{2}\)
CCR\d{1,3}
Myd\d{1,3}
\(\d\)
gene \d
Foxp\d
Tr\d
YKT\d{1,3}
VAMP\d{1,3}
syntaxin-\d{1,3}
SNAP\d{1,3}
\d{1,3} SNAREs?
Munc\d{1,3}
Sec\d{1,2}
\[\d{3}\,\s?\d{3}\]
Exo\d{1,3}
\[\d{2}, \[\d{3}\]
RAB\d
ARHGEF\d{1,3}
Rab\d{1,3}
MICAL\d{1,3}
Rab\dIP\d
ERC\d{1,3}
CAST\d{1,3}
figure \d{1,2}
Cab\d{1,3}
Eg\d{1,3}
ApoB\d{1,4}
FAPP\d{1,3}
SYT\d{1,3}
SDC\d{1,3}
SPCA\d{1,3}
Syndecan-\d
cofilin-\d{1,3}
ATPase \d{1,3}
APEX\d{1,3}
CtBP\d{1,3}
Arf\d{1,3}
GBF\d{1,3}
KIF\d{1,3}B
KIF\d{1,3}A
kinesin-\d{1,3}
LAMP\d{1,3}
Vps\d{1,3}
Lamp\d{1,3}
\[\d{1,3}\,\s?\d{1,3}\]
Chs\d{1,3}
Bud\d{1,3}
Bch\d{1,3}
PKD\d{1,3}
ARF\d{1,3}
PRKD\d{1,3}
PLEKHA\d
AP\d{1,3}
\d{4}'s
\d{1,4} leucines
p\d+ protein
ERGIC-\d{1,3}
LMAN\d{1,3}
\d+ inches
withstand \d+
\d+-inch
\d+ for
\d+ feet
examinations \d{1,4}
annually \d+
males \d+
queens \d+
manufacturer \d+
stock \d{1,3}
www\d\.
\d-bp [a-zA-Z]+
\(p\d{1,3} gag\)
\d{1,2} loci
\d{1,4} loci
the \d\,\d{3}\,\d{3}
only \d{1,3}\,\d{1,3}
lowest \d+
after \d{4}
Fig\.\s\d+\.\d+
\d+\sto\s\d+
\d{3}[\,\.-]\d{3}
FIGURE\s\d+\.\d+
ly\s\d+
cases\.\d+
the \d+
In \d+
reported \d+\,\d+
Akt\d+
\d+ were
of >\d+
of <\d+
dataset \d+
miR\d+
TRAF\d+
around \d+
\d+′UTRs
\d+′UTR
reach \d+ \d+
exceeding \d+
\d+′ bias
SHP-\d+
\d+ methods
\d+ because
DENV-\d+
ORF\d+\. \d+
\d+\.\d+ kDa
\d+ Prior
\d+ Structure
PRD\d+
particles \d+
2D
\d+ The
\d+ STIV
reduction \d+
\d+ Decreased
SSO\d+
contains \d+
hdrC-\d+
SO\d+
CLUSTAL \d+\.\d+
Advance \d+\.\d+
1D
cgi\) \d+
\d+(\.\d+)? to \d+(\,\d+)?(\.\d+)?
\d+ nl
\d+ CapLC
version \d(\.\d)*
\d\.\d M [a-zA-Z]{2,5}
\d+(\,\d+)+(\.\d+)? RPM
OD\d+
\d+(\,\d+)*(\.\d+)? and
\d+(\,\d+)*(\.\d+)? fold
Cy\d+
\d+(\,\d+)*(\.\d+)?-cm
\d+(\,\d+)*(\.\d+)?h
elsewhere \d+
\d-DE
\d+(\,\d+)*(\.\d+)?-mM
described \d+
systems \d+
SIRV\d+
reported \d+
3rd
Bayle \d+ \d+
[a-zA-Z]{4,15} \d \,
\(T\d\)
\d{3}-\d{4}
T\d+
\(BCS \d+-\d+\)
\(fig\,\s\d{1,2}\)
Pik\d+
Nir\d+
MYO\d+A
ACBD\d+
\d+-kinases
The\s\d{4}
Fig\.\s?\d{1,2}
\d+[\s-]L
December\s\d{1,2}
HIV-\d+
NS\d+A
S\d+T
genotype \d+
table \d+
\d+-[a-zA-Z]+
[a-zA-Z]+\d+[a-zA-Z]+
[a-zA-Z]+\d+/[a-zA-Z]+\d+
\d+ few
\d+-\d+
\d+/\d+
\d+(\,\d+)*(\.\d+)? years
\d+(\,\d+)*(\.\d+)? dian
from \d+(\,\d+)*(\.\d+)?
per \d+(\,\d+)*(\.\d+)?
and \d+(\,\d+)*(\.\d+)?
per \d+(\,\d+)*(\.\d+)?
\d+(\,\d+)*(\.\d+)? cases
RV\d+
\d+(\,\d+)*(\.\d+)?\sgramicidin
P/L\s=\s\d+(\,\d+)*(\.\d+)?
CH\s\d+
\d+(\,\d+)*(\.\d+)?\skeV
R\d+
N\d+
\d+′ UTR
PK \d+
\d+C
increased\d+
itself \d+\, \d+
with \d+\,\s?\d+
\d+(\.\d+)? ml
day \d+(\,\d+)*(\.\d+)?
\d = \d
\d+/[a-zA-Z]
covid19
as \d+
set \d+
\d+′-adjacent
Gal\d+
\d+K
Phe\d+
Mutant\s?\d+\.\d+
than \d+(,[\s\d]+)?
G\d+
Frame\s?\d+
RPS\d+
Dog \d+
TFF\d+
[a-zA-Z]{3,20}\d+
D\d+
age \d+(\,\d+)*(\.\d+)?
NL\d+
risk \d+(\,\d+)*(\.\d+)?
WHO,\s?\d+\s?\d+
km 2
[a-zA-Z]{2}\d
F1
[a-zA-Z]{4,10}\s\d+(,\s\d+)*
[a-zA-Z]{3,20}\s\d+(\,\d+)*(\.\d+)?
DAMBE\d+ \d+
2?2nd
Figure\s{1,2}\d{1,2}
\d+\s?[µkmn]g
\d+\s?[µmc]L
\d+\s?[mkdc]?m
AY\d+
DQ\d+
Table\s?\d+\s?\.?\s?\d*
Ag \d+
Cd\d+
\d+\s?±\s?\d+
\d+(\,\d+)*(\.\d+)? x \d+ \d+
mm \d
TL \d+
#\d+
F\d+
VN \d+
S\d+
\d+(\,\d+)*(\.\d+)? pg
value \d+(\s\d+)*
approximately \d+(\s\d+)*
GMT\+\d+
\([a-zA-Z]\s\d\s\)
CRP/\d+
\d+(\.\d+)?\s?x\s?\d+
[+-]?\d+(\,\d+)*(\.\d+)?\s?x\s?[-+]?\d+(\,\d+)*(\.\d+)?
\[\d+S\]
\[\d+sS\]
SW\d+
\d+/ I
TX\d+
[a-zA-Z]{3,}\.\s?\d+(\s?,\s?\d+)*
[fF]igure?\s\d+(\s?\.\s?\d+)*
[a-zA-Z]{2,}'\s?\d+
FIGURE\s?\d+(\s?\.\s?\d+)*
[tT]able\s*\d+(\s?\.\s?\d+)*
[a-zA-Z]{3,}\d+\.\d+
[a-zA-Z]{3,}\s?\d+[\.\,\s\d]*[a-zA-Z]{2}
pH\s?\d+
g/\d+
[a-zA-Z]{3,}\s?\d+[\.\,\s\d]*
\d+(\,\d+)*(\.\d+)?/\s?\d+(\,\d+)*(\.\d+)?
X\d+
Q\d+
\d+T
\d+(\.\d+)?\s?-\s?\d+(\.\d+)?
[a-zA-Z]{2,}-[a-zA-Z]\d+
B\d+(\.\d+)?
v\d{1,2}
\d+(\.\d+)?\ss
Re\s?[=<>]\s?\d+(\.\d+)?
\d+\snM
\d{2}/\d{2}/\d{2}
E\d+
L\d+
CC\s?\d+
\d+′-[CATG]+
et a[l1] \d{4}
[a-zA-Z]{3,}_\d+
[a-zA-Z]{2}\d+(\.\d)?
([Ff]ig\.?|[Ff]igure|[Tt]able|TABLE|FIGURE|[Ss]ection|[sS]ec\.?)\s\d+(\s?[.,]\s?\d+)?
θ\s?\d
(\d+(\,\d+)*(\.\d+)?\s?−)?\s?\d+(\,\d+)*(\.\d+)?\s?mg
V\d+
K\d+
EC \d+
[mM]\d+
\d+,\s[a-zA-Z]{3,}
[a-zA-Z]{3,},\s?\d+
t[-−]\d
t[−-]\d
